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A B S T R A C T
Background: Autoimmune inﬂammatory disease increases the risk of diﬀuse large B-cell lymphoma (DLBCL) and
marginal zone lymphoma (MZL), but ﬁndings for other mature B-cell malignancies are equivocal. Furthermore,
it has been suggested that the increase in DLBCL is due to the activated B-cell (ABC) subtype; but data on this,
and the impact of inﬂammatory co-morbidities on survival, are sparse and contradictory.
Methods: Data are from an established UK population-based cohort. Patients (n=6834) diagnosed between 01/
2009 and 08/2015 are included; DLBCL (n= 1771), myeloma (n= 1760), chronic lymphocytic leukaemia (CLL,
n= 1580), MZL (n=936), and follicular lymphoma (FL, n= 787). Information on rheumatological disorders
and deaths was obtained by record-linkage to nationally compiled Hospital Episode Statistics, with age-and sex-
matched individuals (n= 68,340) from the same catchment population (˜4 million people) providing the
comparator.
Results: Signiﬁcantly increased risks for DLBCL (OR=2.3, 95% CI 1.8–2.8) and MZL (OR=2.0, 95% CI
1.5–2.7) were found for those with rheumatological disorders; the site distribution of those with/without
rheumatological conditions diﬀering for DLBCL (p= 0.007) and MZL (p= 0.002). No increases in risk were
observed for the remaining mature B-cell malignancies, and no associations with survival were detected for
DLBCL (age-adjusted HR=1.2, 95% CI 0.9–1.6) or MZL (age-adjusted HR=1.0, 95% CI 0.6–1.9). Furthermore,
whilst our ﬁndings provide evidence for an association with rheumatological disease severity for DLBCL, they
oﬀer little support for the notion that the association is driven by an increase in the incidence of the ABC
subtype.
Conclusion: Our ﬁndings support the hypothesis that the chronic activation and proliferation of speciﬁc B-cell
populations which characterize autoimmune disease increase the potential for the lymphomagenic events that
lead to DLBCL and MZL in both males and females; but have no impact on the development of CLL, FL or MM, or
on survival.
1. Introduction
Arising from the malignant transformation of lymphoid cells, lym-
phoid neoplasms are the fourth most common cancer subtype in men
(after prostate, lung, and colorectal) and women (after breast, lung, and
colorectal) [1,2]. Including chronic lymphocytic leukaemia (CLL), the
lymphomas and multiple myeloma (MM), this diverse cancer group is
dominated by mature B-cell tumours, which account for around 90% of
the total [2–4]. Immune dysregulation plays a pivotal role in the
development of mature B-cell malignancies and several autoimmune
conditions have been linked with increased risk. Among the strongest
and most consistently reported associations are those between B-cell
lymphomas – particularly diﬀuse large B-cell lymphoma (DLBCL) and
marginal zone lymphoma (MZL) – and chronic B-cell-activating in-
ﬂammatory diseases notably rheumatoid arthritis, systemic lupus er-
ythematosus and Sjögren’s syndrome [4–11]. Furthermore, there is
some evidence to suggest that DLBCL patients with chronic in-
ﬂammatory conditions are more likely to be diagnosed with the
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activated B-cell (ABC) subtype [5,12], which has a poorer prognosis
than the germinal centre B-cell (GCB) subtype and tends to be diag-
nosed at a slightly older age [13,14].
More recently, interest in the impact that autoimmune conditions
(and their treatments) could have on the survival of patients with
mature B-cell neoplasms has been growing [15–18]. The complexity of
both groups of disorders, coupled with the rapidly changing treatment
landscape, means that data on this topic are comparatively sparse, and
the few studies that have investigated this issue have produced con-
tradictory results [15–18]. Accordingly, examining both aetiological
associations and survival in a well-established contemporary popula-
tion-based UK cohort of patients with haematological malignancies
[19,20], the present report describes the relationship between rheu-
matological disorders and the ﬁve commonest mature B-cell malig-
nancies; namely DLBCL, MZL, FL, CLL and MM.
2. Materials and methods
2.1. Setting
The study is set within the UK’s Haematological Malignancy
Research Network (HMRN) which, initiated 09/2004 with a catchment
population approaching 4 million accrues ˜2400 haematological ma-
lignancy diagnoses each year, provides contemporary real-world data
that can be generalized to the UK as a whole (www.hmrn.org) [19].
HMRN has two population-based cohorts at its core, a patient cohort
and a general population cohort; full details of the former’s structure,
data collection methods, and ethical approvals are provided elsewhere
[19,20]. Brieﬂy, HMRN operates under a legal basis that permits full
treatment and outcome data to be collected from clinical records
without explicit consent, and both cohorts are linked to nationwide
information on deaths, cancer registrations and Hospital Episode Sta-
tistics (HES) [20]. All patient cohort diagnoses, including progressions
and transformations, are reported and coded to the latest WHO ICD-O3
[4] by haematopathologists at the Haematological Malignancy Diag-
nostic Service (HMDS); a fully integrated specialist laboratory housing
all of the technology and expertise required for the diagnosis and
monitoring of haematological cancers (www.hmds.info) [21–23]. Pa-
tient cohort members diagnosed between 01/2009 and 12/2015 were
matched at the point of diagnosis on age and sex to 10 randomly se-
lected individuals from the same catchment population from the na-
tional population-based NHS Central Register by NHS Digital (https://
digital.nhs.uk/). These general population-cohort members were as-
signed a “pseudo-diagnosis” date corresponding with their matched
cases’ diagnosis date, and none had a record of a previous cancer re-
gistration for a haematological malignancy.
2.2. Study population
This report includes 6834 patients newly diagnosed 01/2009-07/
2015 with one of the ﬁve commonest mature B-cell malignancies,
DLBCL (n=1771), MM (n= 1760), CLL (n= 1580), MZL (n=936),
or FL (n= 787), and their age- and sex-matched counterparts from the
general population cohort (n=68,340). In addition to examining core
diagnostic/prognostic clinical data, for DLBCL patients with available
data/material we examined cell-of-origin assigned on the basis of: 1)
immunohistochemical expression of CD10, BCL6 and IRF4/MUM1 [24];
and 2) gene-expression proﬁling of pre-treatment biopsies analysed
using the Illumina WG-DASL and DLBCL automatic classiﬁer (DAC)
[13,25,26].
As with many other chronic diseases, hospital admissions for
rheumatological disorders are comparatively rare. However, as detailed
by the UK’s National Institute for Health and Clinical Care Excellence
(NICE), the diagnosis and treatment of autoimmune/inﬂammatory
conditions like rheumatoid arthritis and Sjögren’s Syndrome require
specialist clinical input, and patients are diagnosed and managed as
outpatients in secondary care [27,28]. Hence, for the purposes of the
present analysis, data on all secondary care episodes in both inpatient
and outpatient settings between April 2003 and the date of B-cell ma-
lignancy diagnosis (patient cohort members), or the corresponding
pseudo-diagnosis date (comparator cohort members), were obtained for
all individuals via linkage to HES. Within HES, each episode of hospital
care is assigned to an individual consultant, which in turn is linked to
their clinical specialty categorization. For the purposes of the present
analysis, each rheumatology episode was deﬁned either as a face-to-
face outpatient attendance or as a hospital admission under the care of
the rheumatology specialty.
A case-control approach was used to quantify associations between
rheumatology episodes and malignancy; odds ratios (ORs) and 95%
conﬁdence intervals (CIs) being estimated using conditional logistic
regression. Monte-Carlo simulation techniques were used to estimate p-
values when cell numbers were ≤ 5 [29]. The potential impact of
rheumatological disease on survival was also examined among the
cases; overall survival (OS) and hazard ratios (HRs) from Cox propor-
tional hazards models being reported. Analyses were conducted using
Stata 15.1 (StataCorp 2017) and R (R Core Team 2013).
3. Results
Information on hospital episodes under the care of rheumatology
before the diagnosis of a mature B-cell malignancy (cases) or corre-
sponding pseudo-diagnosis (controls) is presented in Fig. 1 and Table 1.
Fig. 1(A to E) shows the annual rheumatology episode rate of cases and
controls for males and females separately; and Table 1 distributes cases
and controls (both sexes combined) according to the number of epi-
sodes experienced, the top section including data on all episodes and
the second and third sections excluding those that occurred within six,
and then twelve, months before diagnosis/pseudo-diagnosis.
The annual rheumatology episode rate among controls is broadly
similar across all panels in Fig. 1; varying little over the course of the
10-year timeframe but, as expected, being signiﬁcantly higher in fe-
males than in males (p < 0.001). Far more variation is, however,
evident among the cases. For DLBCL, both male and female patients had
consistently higher episode rates than their corresponding controls
(Fig. 1A), the diﬀerence escalating in the years leading up to diagnosis.
Although not as pronounced, the pattern for MZL (Fig. 1B) is broadly
similar to that of DLBCL. By contrast, the annual rates for patients with
FL, CLL or MM show far less evidence of systematic variation
(Fig. 1C–E); although it may be worth noting that the average episode
rate for MM (Fig. 1E) is signiﬁcantly raised in both males and females in
the year leading up to diagnosis.
Within the DLBCL case-control group (Table 1), the OR for those
with at least one rheumatology episode compared to those with none
was 1.9 (95% CI 1.6–2.2); the eﬀect being strongest among those with
three or more episodes (OR 2.4, 95% CI 2.0–3.0). When data in the year
before diagnosis were excluded, the association remained; the ORs
being 2.3 (95% CI 1.9–2.8) and 2.3 (95% CI 1.8–2.8) respectively when
data in the 6 months and 12 months before diagnosis were excluded.
The pattern for MZL is broadly similar, the ORs in those with three or
more episodes being 2.2 (95% CI 1.6–2.9) with no data censoring, and
2.1 (95% CI 1.5–2.8) and 2.0 (95% CI 1.5–2.7) respectively for cen-
soring at 6 months and 12 months prior to diagnosis. However, for FL
and MM, no statistically signiﬁcant associations remained when the
data in the 12 months before diagnosis/pseudo-diagnosis were re-
moved. Furthermore, with most ORs being close to one, there is no
evidence of any eﬀects for CLL (Table 1).
Comparing individuals with three or more rheumatology episodes to
those with none, and censoring 12 months before cancer diagnosis,
Fig. 2 presents ORs stratiﬁed by sex, age, number of episodes, and
timing of the ﬁrst recorded episode prior to diagnosis/pseudo-diag-
nosis. Although the frequency of secondary care rheumatology episodes
is consistently higher for females, both among case groups and control
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groups, there is no evidence that sex either modiﬁes or confounds the
association with malignancy; the within subtype sex-speciﬁc ORs being
similar to each other and to the overall OR (Fig. 2). Within the MZL and
FL groups, there is, however, some evidence that age may be acting as
an eﬀect modiﬁer. For MZL, the ORs range from 5.1 (95% CI 2.2–11.9)
in those aged under 60 years through to 0.9 (95% CI 0.4–2) in those 80
years or more (χ2=9.40, p=0.02). Albeit with estimates closer to
unity, a similar pattern is seen for FL (χ2=9.11, p=0.03), where the
OR in those diagnosed aged<60 years stands apart from the rest, and
is signiﬁcantly raised (OR 3.3, 95% CI 1.7–6.2).
With a view to looking at markers of rheumatological disease se-
verity, both the number of rheumatology episodes recorded in HES, and
the time between the ﬁrst recorded episode and diagnosis/pseudo-di-
agnosis were examined (Fig. 2). While the latter marker was not par-
ticularly discriminatory, the former provides some evidence of an eﬀect
for DLBCL; 5% of cases compared to 1.9% of controls having six or more
rheumatology episodes recorded, yielding an OR of 2.9 (95% CI
2.3–3.7), which is more than twice that in the three to ﬁve episode
group (OR 1.3, 95% CI 0.8–2.0). In MZL, ORs were raised in both
groups, with the OR for six or more episodes being only slightly greater
than that for three to ﬁve episodes (OR=2.1, 95% CI 1.5–3.0;
OR=1.8, 95% CI 1.0–3.1 respectively).
To examine the potential impact of rheumatological disease on
outcome following the diagnosis of malignancy, Table 2 compares the
overall survival (OS) of cases with three or more rheumatology episodes
to that of those with none. For DLBCL, the 1-year and 3-year OS of
patients with three or more preceding rheumatology episodes were
59.5% and 46.6%, respectively, which was signiﬁcantly poorer than
that of those with no episodes (68.3% and 58.5%, respectively); the
corresponding Hazard Ratios (HRs) being 1.4 (95% CI 1.0–1.9,
p= 0.04) at 1-year, and 1.4 (95% CI 1.1–1.9, p= 0.01) at 3-years.
However, the 111 patients with three or more episodes were, on
average, signiﬁcantly older than the 1597 who had none (median ages
73.0 and 70.3 years, respectively); and, when age was adjusted for, the
1-year and 3-year HRs dropped to 1.2 (95% CI 0.9–1.6, p= 0.27) and
1.2 (95% CI 0.9–1.6, p= 0.12) respectively. No other statistically sig-
niﬁcant survival diﬀerences in outcome were detected.
Table 3 presents additional prognostic and treatment data for
DLBCL; the most aggressive of the ﬁve mature B-cell malignancies ex-
amined, and the only one that is potentially curable with standardized
ﬁrst-line chemotherapy. In our cohort, 80.2% (1421/1771) of DLBCL
patients received ﬁrst-line potentially curative treatment; those who did
not tending to have a poor performance status and more advanced
disease. As can be seen from Table 3, DLBCL patients with ≥3 rheu-
matology episodes were, however, slightly less likely (p=0.047) to be
treated with curative intent (73.0%, 81/111) than those with none
(81.0%, 1294/1597). Nonetheless, no signiﬁcant survival diﬀerences
between those with ≥3 rheumatology episodes and those with none
remained once the standard prognostic factors (age, performance
status, B-symptoms and cancer stage) were accounted for; either among
the total patient group (HR=1.0, 95% CI 0.8–1.3) or among the 80.0%
who were treated with curative intent (HR=0.9, 95% CI 0.6–1.3).
With a view to gaining further insight into the association between
B-cell lymphomas and rheumatological disorders, we examined re-
lationships with cancer site for MZL and DLBCL, and cell-of-origin for
DLBCL. With respect to the former, as would perhaps be expected, the
Fig. 1. Annual rheumatology episode rates in the 10 years before diagnosis (cases) or pseudo-diagnosis (controls) of A) Diﬀuse large B-cell lymphoma; A) Marginal
zone lymphoma; C) Follicular lymphoma; D) Chronic lymphocytic leukaemia; E) Multiple myeloma: HMRN January 2009 to August 2015.
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site distribution of patients with MZL who had ≥3 rheumatology epi-
sodes diﬀered from that of those with none (p= 0.015, data not
shown); the diﬀerence being partly driven by the relatively high pro-
portion of patients in the rheumatoid group with MZL tumours in the
salivary gland, the only individual site to vary signiﬁcantly (10.6%
versus 1.1% respectively, p= 0.002). However, whilst the exclusion of
these tumours (most likely associated with Sjögren’s syndrome) re-
duced the OR for rheumatology (≥3 episodes versus none, excluding
episodes in the 12 months prior to diagnosis/pseudo-diagnosis) the
eﬀect remained (OR=1.8, 95% CI 1.3–1.4). The site distribution also
diﬀered for DLBCL (p=0.007); the largest diﬀerence being the excess
involvement seen for the rheumatoid group within the epitrochlear
nodes of the arm, the only individual site to vary signiﬁcantly (2.9%
versus 0.1%, p=0.026). The numbers involved were, however, small
(n= 4) and their removal had no impact on the risk estimate.
With respect to cell-of-origin, 47.8% (816/1708) of DLBCL patients
had suﬃcient immunohistochemistry (CD10, BCL6 and IRF4/MUM1) to
enable their tumour to be classiﬁed as either GCB or non-GCB; 47.6%,
(761/1597) of those with no rheumatology episodes, and 49.5% (55/
111) of those with three or more episodes. The proportions of GCB and
non-GCB were similar; GCB accounting for 55.5% (423/761) in those
with no rheumatology episodes and 56.5% (31/55) in those with three
or more (p=0.91). Within the DLBCL subgroup of 505 (29.6%) that
could be categorized on the basis of gene-expression proﬁling (GCB,
ABC, or unclassiﬁed), the ﬁndings were similarly negative (data not
shown).
4. Discussion
Incorporating data on nearly 7000 patients newly diagnosed with
one of the ﬁve commonest mature B-cell malignancies and ten times as
many controls, this large UK population-based record-linkage study
conﬁrmed the well-known association between rheumatological dis-
orders and subsequent DLBCL and MZL development [5,7,15]. By
contrast, highlighting the heterogeneity of this diverse cancer group, no
associations were observed for FL, CLL or MM; again broadly agreeing
with the few studies that have reported on this topic [7,30,31]. Inter-
estingly, however, even though as expected women were signiﬁcantly
more likely than men to have rheumatological episodes, there was little
indication that sex impacted on the strength of the association with B-
cell malignancy. However, we did ﬁnd evidence to support the sug-
gestion that DLBCL risk was increased among those (males and females)
with more severe rheumatological disease; which, in addition to being
consistent with a potential aetiological role for chronic inﬂammation, is
also consistent with the suggestion that intensive immunosuppressive
therapies could have a part to play, although the evidence on this topic
is conﬂicting [15,32–34]. Importantly, our ﬁndings mitigate against the
view that the association between DLBCL and chronic B-cell activating
inﬂammatory diseases is likely to be mediated by an increase in the
incidence of the ABC subtype: no cell-of-origin frequency diﬀerences
with rheumatology status being observed for either of the classiﬁcation
schemas applied to patients with available samples (816/1708). Fur-
thermore, no systematic survival diﬀerences with rheumatology status
were found for DLBCL, or indeed any of the ﬁve malignancies ex-
amined. In this context, it is relevant to note that the cell-of-origin as-
signment methods used in the present report are associated with large
survival diﬀerences in our DLBCL patient cohort, and that this eﬀect
remains even after adjustment for a wide range of established prog-
nostic factors [13].
Major strengths of our study include its large well-deﬁned catch-
ment population; the socio-demographic structure of which, at around
4 million, accounts for around 6% of the UK’s estimated total and is
broadly representative of the national population as a whole in terms of
age, sex, and deprivation [1,19,20]. HMRN’s patient cohort, which sits
within this population, was initiated with the speciﬁc aim of producing
“real-world” generalizable data to inform contemporary clinicalT
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practice and research. Importantly, clinical practice across the region
adheres to national guidelines and, in contrast to most population-
based registers, all patients in the study area beneﬁt from world-class
centralised diagnostics; ensuring accuracy and consistency in the di-
agnostic process, as well as completeness of cancer ascertainment.
Sourced from the same catchment population as the patient cohort, and
linked to the same nationwide administrative databases (deaths, cancer
registrations, and HES), HMRN’s comparison cohort was speciﬁcally
constructed to enable robust comparisons to be made between patients
with haematological malignancies and individuals from the general
population. Furthermore, our use of clinical specialty delivering patient
care is likely to have captured the majority of individuals with active
rheumatological disease since, as detailed in the methods, the diagnosis
and treatment of autoimmune/inﬂammatory conditions in the UK re-
quires specialist clinical input; patients are both diagnosed and man-
aged as outpatients in secondary care [27,28]. Indeed, this is evidenced
by the strong patterns seen within our data, where virtually all “ex-
posed” individuals attending an outpatient rheumatology clinic did so
on three or more occasions.
With respect to weaknesses, while the diagnostic and treatment
details relating to cancer subtypes in HMRN’s patient cohort are su-
perior to most studies, using HES data to categorize “exposure” (in this
case those with and without rheumatological disorders) is clearly less
robust; albeit not subject to the biases commonly associated with stu-
dies based on self-reported illness histories [10,16,17,30,35]. Never-
theless, the fact remains that we could not directly identify diﬀerent
rheumatological disease subtypes, dates of diagnosis, or treatments.
Furthermore, although censoring 12 months before diagnosis/pseudo-
diagnosis hopefully reduced the potential for detection bias resulting
from reverse causality, it is possible that some weaker associations may
have been obscured. The timeframe over which we could investigate
was also limited by the fact that outpatient HES is only available from
2003 onwards and, given the nature of the relationship being in-
vestigated, a longer period would have been preferable. The analyses
presented here have, however, demonstrated the utility of HES data for
investigations of this type; and it is possible that changes in national
recording procedures may facilitate more detailed analyses in the fu-
ture.
5. Conclusions
Our ﬁndings support the hypothesis that the chronic activation and
proliferation of speciﬁc B-cell populations which characterize auto-
immune diseases like rheumatoid arthritis and Sjögren’s syndrome,
increase the potential for the lymphomagenic events that lead to DLBCL
and MZL in both males and females; but have no impact on the de-
velopment of CLL, FL or MM. In addition, for DLBCL, whilst our ﬁndings
provide evidence for an association with rheumatological disease se-
verity, they oﬀer little support for the notion that the association is
driven by an increase in the ABC subtype. More importantly, perhaps,
the observation that individuals with chronic inﬂammatory disorders
are not additionally disadvantaged with respect to cancer survival, of-
fers some reassurance to patients with these conditions, as well as to the
clinicians who treat them.
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Fig. 2. Mature B-cell malignancy cases and controls with three of more rheumatology episodes, Odds Ratios (OR) and 95% Conﬁdence Intervals (CI), distributed by
sex, age, number of episodes, and number of years between the ﬁrst episode and diagnosis/pseudo-diagnosis of A) Diﬀuse large B-cell lymphoma; A) Marginal zone
lymphoma; C) Follicular lymphoma; D) Chronic lymphocytic leukaemia; E) Multiple myeloma: HMRN diagnoses 2009 to 2015.
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Table 2
Numbers, median ages, Overall Survival (OS) and Hazard Ratios (HR) of patients with no rheumatology episodes, and those with three or more rheumatology episodes distributed by diagnostic category (episodes in the
year before diagnosis are excluded): HMRN diagnoses 2009–2015, followed-up to 05/07/2018.
Cases, N(%) Age1, median(IQR) 1-year OS, % (95%CI)2 HR(95%CI), unadjusted HR(95%CI), adjusted3 3-year Overall Survival1, % (95%CI) HR(95%CI), unadjusted HR(95%CI), adjusted3
Diﬀuse large B-cell lymphoma 1771(100.0) 70.6(61.1–79.1) 67.4(65.2–69.5) 57.4(55.1–59.7)
Rheumatology episodes
None 1597(90.2) 70.3(60.7–78.9) 68.3(65.9–70.5) 1(ref) 1(ref) 58.5(56.0–60.8) 1(ref) 1(ref)
≥3 111(6.3) 73.0(66.3–79.7) 59.5(49.7–67.9) 1.4(1.0–1.9) 1.2(0.9–1.6) 46.6(37.0–55.6) 1.4(1.1–1.9) 1.2(0.9–1.6)
Z=−3.01, p < 0.01 χ2=4.32, p= 0.04 χ2=6.80, p < 0.01
Marginal zone lymphoma 936(100.0) 72.4(64.4–79.5) 90.1(88.0–91.8) 74.5(71.6–77.2)
Rheumatology episodes
None 840(89.7) 72.6(64.6–79.6) 90.1(87.9–92.0) 1(ref) 1(ref) 74.5(71.4–77.3) 1(ref) 1(ref)
≥3 52(5.6) 70.9(63.0–77.6) 90.4(78.4–95.9) 1.0(0.4–2.4) 1.3(0.5–3.2) 78.8(64.9–87.6) 0.8(0.4–1.5) 1.0(0.6–1.9)
Z= 1.41, p=0.16 χ2=0.01, p= 0.96 χ2=0.40, p=0.53
Follicular lymphoma 787(100.0) 65.3(56.2–73.8) 94.8(93.0–96.1) 85.4(82.7–87.7)
Rheumatology episodes
None 726(92.2) 65.6(56.2–73.8) 94.6(92.7–96.0) 1(ref) 1(ref) 85.0(82.1–87.4) 1(ref) 1(ref)
≥3 36(4.6) 63.0(56.8–75.8) 97.2(81.9–99.6) 0.5(0.1–3.7) 0.6(0.1–4.4) 91.1(75.0–97.1) 0.5(0.2–1.7) 0.6(0.2–1.9)
Z= 0.41, p=0.68 χ2=0.45, p= 0.50 χ2=1.20, p=0.28
Chronic lymphocytic leukaemia 1580(100.0) 71.1(62.9–78.9) 90.9(89.4–92.2) 79.9(77.8–81.8)
Rheumatology episodes
None 1490(94.3) 71.0(62.8–78.9) 90.7(89.2–92.1) 1(ref) 1(ref) 80.2(78.0–82.1) 1(ref) 1(ref)
≥3 40(2.5) 75.7(70.6–82.1) 92.5(78.5–97.5) 0.8(0.3–2.6) 0.6(0.2–1.9) 67.2(50.3–79.5) 1.8(1.0–3.1) 1.4(0.8–2.4)
Z=−2.71, p < 0.01 χ2=0.11, p= 0.74 χ2=4.30, p=0.04
Multiple myeloma 1760(100.0) 72.6(64.3–79.8) 75.1(73.0–77.0) 55.6(53.2–57.9)
Rheumatology episodes
None 1647(93.6) 72.7(64.5–79.8) 74.9(72.8–76.9) 1(ref) 1(ref) 56.0(53.6–58.4) 1(ref) 1(ref)
≥3 54(3.1) 67.6(63.8–76.3) 75.9(62.2–85.2) 1.0(0.6–1.7) 1.1(0.6–1.9) 48.0(34.2–60.5) 1.3(0.9–1.8) 1.4(1.0–2.1)
Z= 1.64, p=0.10 χ2=0.01, p= 0.92 χ2=1.40, p=0.24
1 Wilcoxon rank-sum test was used to compare age distributions.
2 Log rank test was used to test for survival diﬀerences.
3 Adjusted for age.
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